Middeløgningen fra baseline i% forudsagde, at FEV1 var 0, 6% i montelukastbehandlingsgruppen og 2, 7% i fluticasonbehandlingsgruppen.
The mean increase from baseline in% predicted FEV1 was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group.